The global hepatitis therapeutics market size accounted for USD 17.02 billion in 2024, grew to USD 17.8 billion in 2025 and is predicted to surpass around USD 26.66 billion by 2034, representing a healthy CAGR of 4.59% between 2024 and 2034. The North America hepatitis therapeutics market size is calculated at USD 7.49 billion in 2024 and is expected to grow at a fastest CAGR of 4.69% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hepatitis Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hepatitis Therapeutics Market, by Disease Type, 2024-2034
8.1.1. Hepatitis A
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Hepatitis B
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Hepatitis C
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Hepatitis Therapeutics Market, by Distribution Channel, 2024-2034
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Drug Stores and Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Online Providers
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Disease Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1. Gilead Lifesciences
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bristol-Myers Squibb Co
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Biocon
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AbbVie
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Merck & Co., Inc.,
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Johnson & Johnson
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Roche
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Novartis
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sanofi
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Cipla
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample